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Objectives: To assess the pharmacological treatment and the control of major modifiable
cardiovascular risk factors in everyday practice according to the patients’ cardiovascular risk level.
Methods: In a cross-sectional study general practitioners (GPs) had to identify a random sample
of their patients with cardiovascular risk factors or diseases and collect essential data on the
pharmacological treatment and control of hypertension, hyperlipidemia, and diabetes according to
the patients’ cardiovascular risk level and history of cardiovascular disease. Participants were
subjects of both sexes, aged 40–80 years, with at least one known cardiovascular risk factor or a
history of cardiovascular diseases.
Results: From June to December 2000, 162 Italian GPs enrolled 3120 of their patients (2470
hypertensives, 1373 hyperlipidemics, and 604 diabetics). Despite the positive association between
the perceived level of global cardiovascular risk and lipid-lowering drug prescriptions in
hyperlipidemic subjects (from 26% for lowest risk to 56% for highest risk p < 0.0001) or the
prescription of combination therapy in hypertensives (from 41% to 70%, p < 0.0001) and diabetics
(from 24% to 43%, p = 0.057), control was still inadequate in 48% of diabetics, 77% of
hypertensives, and 85% of hyperlipidemics, with no increase in patients at highest risk. Trends for
treatment and control were similar in patients with cardiovascular diseases.
Conclusions: Even in high-risk patients, despite a tendency towards more intensive treatment,
pharmacological therapy is still under used and the degree of control of blood pressure, cholesterol
level and diabetes is largely unsatisfactory.
Keywords: global cardiovascular risk, hypertension, hyperlipideamia, diabetes, general practice.
Introduction
Epidemiological surveys consistently report under-utilization of evidence-based
preventive treatments and inadequate control of modifiable risk factors in the overall
population at cardiovascular risk (Dunn and Bough 1996; Avanzini et al 1998; Bouma
M et al 1999; Primatesta and Poulter 2000; EUROASPIRE II Study Group 2001;
Hippisley-Cox and Pringles 2001; Primatesta et al 2001; Gianpaoli and Vanuzzo 2003;
Pilotto et al 2004; Bhatt et al 2006). As the absolute benefits of treatments for the
prevention of cardiovascular diseases are directly proportional to patients’ global
cardiovascular risk, priority should clearly be given to patients at high risk (Wood et al
1998; Ansell et al 1999; European Diabetes Policy Group 1999; 1999 WHO/ISH 1999).
However, little information is available, to our knowledge, on the degree of treatment
and control of cardiovascular risk factors in relation to patients’ absolute risk (Amar
et al 2002; Camisasca et al 2002; Lloyd-Jones et al 2002). General practitioners (GPs)
identify subjects at high cardiovascular risk properly (Roncaglioni et al 2004), but it is
not known whether this perception leads to more intensive treatment and better control
of their risk factors.Vascular Health and Risk Management 2006:2(4) 508
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As part of the feasibility phase of a large intervention
study on the optimization of cardiovascular prevention in
high-risk patients (Risk & Prevention Study, Clinical Trial.gov
number, NCT00317707 [ClinicalTrial.gov]), we ran a pilot
epidemiological study to assess the level of treatment and
control of the three major modifiable cardiovascular
risk factors— arterial hypertension, hyperlipidemia and
diabetes— in everyday practice, according to patients’
absolute levels of cardiovascular risk.
Methods
A network of GPs from all over Italy was invited to enter a
cross-sectional study on the cardiovascular preventive
strategies adopted in everyday practice. General practitioners
were members of research working parties who have
participated in previous collaborative studies with our
Institute. Among all subjects coming to the surgery for any
reasons from June to December 2000 each GP identified a
random sample of patients aged 40–80 perceived as being at
cardiovascular risk because of at least one risk factor or
atherosclerotic disease. All patients who met these criteria
were consecutively entered in a register in which a random
sequence picked out one in ten for inclusion in the study for
up to 20 patients. We estimate that a sample of at least 100
general practitioners (GPs) recruiting a total of 2000 patients
would have been enough to detect the percentage of control
of major risk factors in the four pre-specified risk level
categories, with sufficient accuracy.
GPs had to collect data on cardiovascular risk factors
(history of hypertension, diabetes, hyperlipidemia, if patients
were obese, current smokers, or had a family history of
premature myocardial infarction) and on the history of
cardiovascular diseases (CVD) including myocardial
infarction (MI), angina pectoris, arterial revascularization
procedures (CABG or PTCA), stroke, transient ischemic attack
(TIA), peripheral arterial occlusive disease (PAOD), GPs were
also asked to do a physical examination (including measuring
blood pressure [BP], height, and weight) and record the results
of recent laboratory tests (plasma lipids and glucose in all
patients and HbA1c in diabetics). On the basis of all the data,
GPs were asked to subjectively estimate for each patient the
overall level of cardiovascular risk, rating it as mild, moderate,
high, or very high (Roncaglioni et al 2004). Patients’ risk
was also classified according to whether they already had a
history of CVD.
Hypertensives were considered well-controlled when BP
was <140/90 mmHg if not diabetics, and <130/80 mmHg if
diabetics; hyperlipidemics when total plasma cholesterol
was  <190 mg/dL and diabetics when blood HbA1c was
≤7.5 mg% (Wood 1998).
In interpreting the use of lipid-lowering drugs we must
bear in mind the restrictions on their prescription imposed
by the Italian National Health Service in patients at low-
moderate cardiovascular risk.
Statistical analysis
Descriptive results are expressed as numbers and percentages.
The proportions of subjects treated and controlled, with or
without CVD, were compared using the χ
2 test. The same
analysis according to the level of risk was done using the χ
 2
test for trend. Tests were two-sided and a value of p < 0.05
was considered significant. Statistical analyses were done
using the statistical package SAS
® (SAS Institute, Cary, NC).
Results
A total of 162 GPs took part in this study and recruited 3120
patients between June and December 2000. As a whole, 41%
of this population had a history of CVD; 40% had 3 or more
risk factors, 15% had 2, and 4% had just 1 risk factor.
A BP measure was available in all 2470 hypertensives, a
recent measure of total plasma cholesterol was available
in 1373 out of 1627 hyperlipidemics (84%) and blood
HbA1c in 604 out of 635 diabetics (95%). Only patients
with complete data (2914) were included in the present
analysis and their characteristics are shown in Table 1. Table 2
shows the distribution of hypertensive, hyperlipidemic, and
diabetic patients according to the level of global
cardiovascular risk perceived by their GP and the presence of
CVD.
Preventive treatment of risk factors
Figure 1 shows the rate of specific pharmacological
treatments of patients with risk factors; 96% of hypertensives
were pharmacologically treated, 78% of diabetics, and 46%
of hyperlipidemics.
ACE-inhibitors, diuretics, and calcium antagonists were
the drugs most frequently used in hypertensive patients,
respectively in 53%, 47%, and 39%; 62% of hypertensive
patients were treated with 2 or more drugs. In hyperlipidemic
patients, statins were the drugs most used (87%); 1% received
a combination of 2 drugs. Among diabetic patients 40% were
treated with monotherapy (22% with sulphonylureas, 6%
biguanides, 11% insulin, and 1% acarbose); 38% received a
combination.Vascular Health and Risk Management 2006:2(4) 509
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Figure 2A shows the relation between the prescription of
preventive drug therapy and GPs’ risk perception. In
hyperlipidemic subjects, there was a significant pattern in the
treatment rate, rising from 27% of patients perceived to be at
low risk to 61% of subjects at very high cardiovascular risk
(p < 0.0001). In hypertensive and diabetic patients there was a
trend between the number of drugs prescribed and GPs’ risk
perception (p < 0.0001 for hypertensives; p = 0.057 for diabetics).
A similar pattern was found on analyzing the drug
prescriptions according to the presence of CVD (Figure 2B).
The numbers of hyperlipidemics given drugs and of
hypertensive and diabetics treated with a combination
therapy were higher in patients with CVD: from 38% up to
61% in hyperlipidemics (p < 0.0001), from 56% up to 68%
in hypertensives (p < 0.0001), and from 35% up to 43% in
diabetics (p = 0.0633).
The presence and intensity of treatment of each risk factor
was not influenced by the concomitant use of drugs for the
other two risk factors: two or more drugs were used in 59% of
cases when hypertension was the only risk factor, in 58% of
patients also using statins or antidiabetic drugs and in 64%
of those taking both. Findings were similar in diabetic patients
and hyperlypidemics.
Control of risk factors
Overall, control was adequate in 55% of diabetics, 29% of
hypertensives, and 10% of hyperlipidemics. Figure 3A shows
the levels of control according to GPs’ subjective risk grading.
Control was not better in hypertensive and hyperlipidemic
patients perceived at higher risk, and in diabetics, control
was significantly worse in patients at higher cardiovascular
risk (p < 0.0001).
Table 1 Main characteristics of the populationa
Hypertensives Hyperlipidemics Diabetics Total population
(n = 2470) (n = 1373) (n = 604) (n = 2914)
mean age (±SD) 64.5 ± 9.1 63.7 ± 8.8 65.2 ± 8.2 64.1 ± 9.2
age ≥65 years 1375 (56%) 690 (50%) 353 (58%) 1559 (54%)
male 1161 (47%) 641 (47%) 298 (49%) 1406 (48%)
Cardiovascular risk factors
hypertension 2470 (100%) 1018 (74%) 453 (75%) 2470 (85%)
hyperlipidemia 1224 (50%) 1373 (100%) 310 (51%) 1373 (47%)
diabetes 561 (23%) 322 (23%) 604 (100%) 604 (21%)
obesity 700 (28%) 343 (25%) 208 (34%) 772 (26%)
cigarette smoking 390 (16%) 236 (17%) 84 (14%) 485 (17%)
family history of premature myocardial infarction 416 (17%) 287 (21%) 83 (14%) 501 (17%)
History of cardiovascular diseases
previous myocardial infarction 261 (11%) 213 (16%) 86 (14%) 339 (12%)
previous stroke 77 (3%) 47 (3%) 20 (3%) 86 (3%)
previous transient ischemic attack 173 (7%) 89 (6%) 48 (8%) 190 (7%)
previous revascularization 166 (7%) 155 (11%) 59 (10%) 235 (8%)
angina pectoris 234 (9%) 167 (12%) 78 (13%) 287 (10%)
peripheral arterial occlusive disease 160 (6%) 96 (7%) 66 (11%) 183 (6%)
aMost patients had more than one risk factor or cardiovascular disease, so the sum of the columns may exceed the total population studied.
Table 2 Distribution of hypertensive, hyperlipidaemic and diabetic patients according to the level of global cardiovascular risk
perceived by GPs and the history of cardiovascular disease
Level of global cardiovascular risk History of cardiovascular disease
low moderate high very high no yes
Hypertensives (n = 2470) 390 (16%) 1003 (41%) 841 (34%) 229 (9%) 1781 (72%) 689 (28%)
Hyperlipidemics (n = 1373) 131 (10%) 547 (40%) 523 (38%) 166 (12%) 898 (65%) 475 (35%)
Diabetics (n = 604) 32 (5%) 174 (29%) 281 (47%) 116 (19%) 397 (66%) 207 (34%)
Total (n = 2914) 464 (16%) 1190 (41%) 989 (34%) 262 (9%) 2070 (71%) 844 (29%)Vascular Health and Risk Management 2006:2(4) 510
Roccatagliata et al
Figure 1 Treatment and control of hypertension, hyperlipidemia, and diabetes
Figure 2 Drug therapy in hypertension, hyperlipidemia, and diabetics according to level of global cardiovascular risk perceived by GPs (A) and the history of
cardiovascular disease (CVD) (B)
Analyzing data according to the history of CVD, no
significant differences in the rate of control of hypertensive
and diabetic patients were observed; a higher rate of control
was found in hyperlipidemic patients with CVD in respect to
those without (17% vs 6%, p < 0.001).
Pharmacological therapy to control hyperlipidemia was
more frequently required in patients at high or very high
cardiovascular risk (72%) than in patients at low or moderate
risk (48%). Analagously, to control hypertension and diabetes,
combination therapies were more frequently required in
patients at high or very high cardiovascular risk (66% and
32%, respectively) than in patients at low or moderate risk
(55% and 25%, respectively). Similar results were found on
analyzing the pharmacological therapy required to control
the three risk factors according to the presence of CVD.
Among subjects at high or very high cardiovascular risk,
48% with uncontrolled hyperlipidemia were not receiving
drug therapy, and 33% and 52%, respectively, with uncontrolled
hypertension and diabetes were receiving no drugs or
monotherapy. Similar results were found on analyzing subjects
with established CVD and uncontrolled risk factors Being
under chronic therapy for other cardio-vascular risk factors
at the same time did not significantly change the rate of control
of the risk factor considered.
Discussion
This study clearly shows how in daily practice many effective
strategies to prevent cardiovascular diseases are still under-
used even in patients at high cardiovascular risk.
In fact, despite the proportion of hyperlipidemics treated
with lipid-lowering agents and of diabetics and hypertensives
using combination therapies was higher in patients at higher
risk or with previous CVD, this is still inadequate to reach
the therapeutic goals in the majority of patients.
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Besides confirming other findings on the overall low rate
of control of hypertension, hyperlipidemia and diabetes in
current practice (Bouma M et al 1999; Dunn and Bough
1996; Avanzini et al 1998; Primatesta and Poulter 2000;
EUROASPIRE II Study Group 2001; Hippisley-Cox and
Pringles 2001; Primatesta et al 2001; Gianpaoli and Vanuzzo
2003; Pilotto et al 2004; Bhatt et al 2006), the lack of control
even in patients at higher risk of developing CVD in a short
time proves that the global level of risk has not yet become a
fundamental tool for the implementation of preventive
strategies in everyday practice. The consequences are
epidemiologically important considering the prevalence of
patients at high cardiovascular risk: in our population half of
hypertensives and hyperlipidemics and two out of three
diabetics were considered by their GP to be at high or very
high risk of CVD in the next few years, while over a quarter of
patients with hypertension and over a third of those with
diabetes and hyperlipidemia had already suffered a CVD.
The fact that some of them are likely to have more severe
forms of hypertension, hyperlipidemia, and diabetes, often
with target organ damage or concomitant diseases, means
they need much more aggressive treatment to obtain all the
possible benefits. The large margin for improvement is
documented by the fact that one out of three uncontrolled
hypertensives and half the uncontrolled diabetics at higher
cardiovascular risk were given monotherapy or no drugs
at all, and that half the uncontrolled hyperlipidemics at
higher risk were not treated. Although we did not collect
data on non-pharmacological treatments, it is likely that a
closer life style management could significantly improve
the control of hypertension, hyperlipidemia and diabetes.
There have been many reports that aggressive treatment of
risk factors can lead to an optimal level of control in the majority
of patients at high cardiovascular risk (UK Prospective
Diabetes Study (UKPDS) Group 1998a, 1998b; PROGRESS
Collaborative Group 2001; Heart Protection Study
Collaborative Group 2002; Pepine et al 2003; Cannon et al
2004); however, these data come from clinical trials, where
compliance is expected to be better than in routine practice.
We collected no data on this point in our survey, but the far-
from-optimal level of control of modifiable risk factors might
actually reflect not only the GPs’ attitude to prescribing
preventive treatments but also the patients’ resistance to taking
numerous pills for asymptomatic conditions or poor
compliance anyway in the long term. Compliance with
preventive treatments would probably increase if people were
more aware of their risks (Ferrario et al 2004), and more
information from GPs on the long-term benefits of preventive
drugs could reduce the fear of lifelong therapies.
The absence of any negative interaction in our patients
among the drugs used for hypertension, diabetes and
hyperlipidemia should make it possible to optimise these
therapies even in patients at high cardiovascular risk because
of several simultaneous risk factors. The possibility of using
poly-pills, which combine in the same pill different drugs to
control several risk factors simultaneously, may help make
the treatment of multiple risk factors easier and more
acceptable (Wald and Law 2003; Sleight et al 2006). In
addition, the imminent arrival of generic statins might
mitigate the current Italian restriction and could favour their
use also in patients with a lower level of risk (Moon 2006).
Apart from GPs’ and patients’ roles, the presence of specific
contraindications and the appearance of side effects may affect
the use of preventive drug treatments. However, the large
Figure 3 Control of hypertension, hyperlipidemia, and diabetes according to level of global cardiovascular risk perceived by GPs and the history of cardiovascular
disease (CVD)
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selection of different pharmacological approaches available to
control hypertension, hyperlipidemia and diabetes means that
only a tiny minority are due to these reasons.
One limitation of this study was the selection of the
population at cardiovascular risk among people coming to
their family doctor for any reason. This could have favored
the inclusion of subjects with uncontrolled risk factors.
Otherwise, these subjects are expected to be more willing to
take drugs and to follow GPs’ advice, too. Anyway this is the
population that would receive immediate benefit if GPs took
a more “aggressive” preventive attitude.
Another possible limit is the unusual way of defining the
level of cardiovascular risk. We preferred to classify the
patients’ risk according to the GPs’ perception because in a
previous analysis we had found these estimates were not only
associated with the patients’ level of risk but were also
independent of the levels of single risk factors, such as BP or
blood cholesterol (Roncaglioni et al 2004). The use of
algorithms or charts would have favored the inclusion of
uncontrolled hypertensive and hyperlipidemic patients in
the high or very high risk categories. In order to overcome
this possible bias, we also classified our population according
to their clinical history of CVD, a recognized way to identify
people at higher risk, obtaining similar results.
A third limit of the study is that participating GPs do not
necessarily represent all Italian GPs. However, it is likely that
GPs who participated voluntarily and without any financial
incentive were those who managed risk factors better and
were more used to complying with recommendations. Thus
our results probably provide an optimistic estimate of the
real behavior.
In conclusion, the central finding of this study is that in
current practice even in high-risk patients, despite a tendency
towards more intensive treatment, pharmacological therapy
is still under used and the degree of control of blood pressure,
cholesterol level and diabetes is largely unsatisfactory. This
leads to the paradox that despite the number of effective
treatments available, subjects at higher risk of CVD in the
short term get little benefit from them. To identify the main
reasons for this and how best to solve it would greatly improve
the effectiveness of cardiovascular preventive treatments and
the prognosis of a large number of people. These are the aims
of a prospective trial on the optimisation of cardiovascular
prevention in patients at high cardiovascular risk that is
currently going on after this epidemiological feasibility
phase.
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